Global Biologics and Biosimilars Competitive Landscape Professional Research Report 2024

Global Biologics and Biosimilars Competitive Landscape Professional Research Report 2024

Research Summary

Biologics are pharmaceutical drugs derived from living organisms, such as proteins, antibodies, or nucleic acids. They are produced using biotechnology processes and are used for the treatment of various diseases, including cancer, autoimmune disorders, and genetic diseases. Biologics are often highly complex and require specialized manufacturing techniques to ensure their safety, efficacy, and consistency. Biosimilars, on the other hand, are biological products that are highly similar to an already approved reference biologic. They are developed to have comparable efficacy, safety, and quality to the reference product and undergo rigorous testing to demonstrate similarity. Biosimilars offer a more affordable alternative to the original biologic, providing increased access to life-saving therapies. They are regulated by health authorities to ensure their quality, efficacy, and safety. Biologics and biosimilars have revolutionized the field of medicine, offering innovative and effective treatment options for patients with various medical conditions.

According to DIResearch's in-depth investigation and research, the global Biologics and Biosimilars market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Biogen, Celltrion, Sobi, 3SBIO, Changchun High Tech, Kanghong Pharma, Innovent Biologics, Gan&Lee, Tonghua Dongbao, United Laboratory etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Biologics and Biosimilars. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Biologics and Biosimilars market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Biologics and Biosimilars market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Biologics and Biosimilars industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Biologics and Biosimilars Include:

Roche

Amgen

AbbVie

Sanofi

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

Biogen

Celltrion

Sobi

3SBIO

Changchun High Tech

Kanghong Pharma

Innovent Biologics

Gan&Lee

Tonghua Dongbao

United Laboratory

Biologics and Biosimilars Product Segment Include:

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Others

Biologics and Biosimilars Product Application Include:

Hospital

Retail Pharmacy

Other

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Biologics and Biosimilars Industry PESTEL Analysis

Chapter 3: Global Biologics and Biosimilars Industry Porter’s Five Forces Analysis

Chapter 4: Global Biologics and Biosimilars Major Regional Market Size and Forecast Analysis

Chapter 5: Global Biologics and Biosimilars Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Biologics and Biosimilars Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Biologics and Biosimilars Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources